Kory Wentworth
Director of Finance/CFO bij ENTRADA THERAPEUTICS, INC.
Vermogen: 1 M $ op 31-03-2024
Profiel
Kory James Wentworth is currently the Chief Financial Officer & Treasurer at Entrada Therapeutics, Inc. Prior to this, he worked as the Executive Director & Corporate Controller at Alexion Pharmaceuticals, Inc. from 2008 to 2017 and as the Treasurer & Vice President-Finance at bluebird bio, Inc. from 2017 to 2020.
He completed his undergraduate degree at Susquehanna University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ENTRADA THERAPEUTICS INC
0.25% | 15-03-2024 | 83 170 ( 0.25% ) | 1 M $ | 31-03-2024 |
Actieve functies van Kory Wentworth
| Bedrijven | Functie | Begin |
|---|---|---|
| ENTRADA THERAPEUTICS, INC. | Director of Finance/CFO | 01-11-2020 |
Eerdere bekende functies van Kory Wentworth
| Bedrijven | Functie | Einde |
|---|---|---|
| BLUEBIRD BIO, INC. | Comptroller/Controller/Auditor | 08-09-2020 |
| ALEXION PHARMACEUTICALS, INC. | Director/Board Member | 01-12-2017 |
Opleiding van Kory Wentworth
| Susquehanna University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| ENTRADA THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
